Results 311 to 320 of about 145,743 (338)
Some of the next articles are maybe not open access.
Affinity-bound antibody–drug conjugates
Nature Biomedical Engineering, 2019Computationally designed antibody–drug conjugates easily self-assemble via affinity ligands that non-covalently link a therapeutic drug to conserved sites on native IgG antibodies.
Christine S. Nervig, Shawn C. Owen
openaire +2 more sources
Antibody–Drug Conjugates in Tumor Therapy
Pharmaceutical Patent Analyst, 2012Antibody-drug conjugates (ADCs) for tumor therapy contain a cytotoxic drug conjugated to a monoclonal antibody (mAb) across a linker. A homing device, the mAb enables the recognition of tumor cells by binding to tumor-specific antigens. The linker is usually cleaved inside the tumor cell or close to the cell surface according to a well-designed ...
Sammet, Benedikt +2 more
openaire +3 more sources
Payloads of Antibody: Drug Conjugates
2015The payload of antibody–drug conjugates (ADCs) is the warhead of ADCs that kills the tumor cells. Three classes of highly potent toxins including maytansinoids, auristatins, and calicheamicins are currently being employed or pursued in the clinic as the payloads of ADCs.
openaire +1 more source
Building Antibody-Drug Conjugates
Chemical & Engineering News Archive, 2014They’re here. Antibody-drug conjugates, target-seeking molecular missiles with lethal payloads, have arrived.
openaire +1 more source
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Signal Transduction and Targeted Therapy, 2022Sifei Han, Chen Shi, Yu Zhang
exaly
Hodgkin lymphoma: A review and update on recent progress
Ca-A Cancer Journal for Clinicians, 2018Satish P Shanbhag, Richard F Ambinder
exaly
Polymer–drug conjugate therapeutics: advances, insights and prospects
Nature Reviews Drug Discovery, 2018Iriny Ekladious +2 more
exaly
Strategies and challenges for the next generation of antibody–drug conjugates
Nature Reviews Drug Discovery, 2017Alain Beck, Charles Marie Dumontet
exaly
First-in-class tissue factor-targeted antibody–drug conjugate secures FDA approval
Nature Reviews Drug Discovery, 2021exaly